Fondaparinux Bioequivalence Study Design [Design Issues]

posted by Kuldeep Namdev – India, 2013-10-31 06:58 (4625 d 04:36 ago) – Posting: # 11832
Views: 2,483

Please suggest about the bioequivalence (BE) study design of Fondaparinux.
For USFDA/EMEA submission, whether the BE study designed shall be based on PD (pharmacodynamic) parameters like for low molecular weight heparins eg. Enoxaprin, Dalteparin etc. or required an approach based on pharmacokinetic parameters (Cmax, AUC).

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
318 visitors (0 registered, 318 guests [including 19 identified bots]).
Forum time: 12:35 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5